Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sawai Now Curbing Shipments for 432 Products
September 24, 2021
- Towa’s Shipment Restriction List Now Expands to 385 Products
September 24, 2021
- RaQualia Grants Global Rights for TRPM8 Blocker to HK Firm
September 24, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Skyrizi’s New Dosage Forms Approved in Japan: AbbVie
September 24, 2021
- Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
- Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
September 24, 2021
- Hisamitsu Invests 200 Million Yen in Kyushu Univ. Regenerative Medicine Startup
September 24, 2021
- KM Biologics Moves Up COVID-19 Vaccine Target, Aims for Rollout in FY2022
September 22, 2021
- Takeda Grabs Japan Rights to Mirum’s Rare Liver Disease Drug
September 22, 2021
- Shionogi President Calls for Approval Systems to Respond to Emergency Situations
September 22, 2021
- COVID-19 Antibody Cocktail Ronapreve Faces Tight Manufacturing Capacity Worldwide: Chugai Chairman
September 22, 2021
- New Heart Failure Drugs Jostling with Different Modes of Action, Offering Variety of Options
September 21, 2021
- Takeda to Offload Non-Core Assets in Latin America to Adium
September 21, 2021
- Takeda, Janssen to Wind Up Reminyl Collaboration in Japan
September 21, 2021
- New Probe Finds No Safety Issues with White Matter Detected in Pfizer Jab
September 21, 2021
- Enhertu Enters Chinese PII Study for 3rd Line Gastric Cancer
September 21, 2021
- World’s First CAR-T Clinical Trial for GM2 Solid Cancers Might Begin by Year-End
September 17, 2021
- Sumitomo Dainippon Expects Twymeeg’s Initial Uptake in Combo, but Eyes 1st Line Monotherapy Use Too
September 17, 2021
- EA Pharma Appoints Eisai Senior VP Hidenori Yabune as President
September 17, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…